TREATMENTS &
RESEARCH

Search the
latest
treatment
information
here.

Dr. Huntley's
Diagnosis
Checklist

Have a symptom?
See what questions
a doctor would ask.
 

Diphtheria

Diphtheria: Excerpt from The 5-Minute Pediatric Consult

Michael J. Smith, MD

Diphtheria - BASICS

Diphtheria - description

Acute infectious disease caused by Corynebacterium diphtheriae; affects primarily the membranes of the upper respiratory tract with the formation of a gray-white pseudomembrane

Diphtheria - general prevention

Active immunization with diphtheria toxoid is the cornerstone of population-based diphtheria prevention. Current recommendations from the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention:

  • Ages 2 months to 7 years: 5 doses of diphtheria vaccine (with tetanus toxoid and acellular pertussis):
    • 1st 3 given as DTaP vaccine 0.5 mL IM at 2-month intervals beginning at 2 months of age
    • 4th dose of DTaP should be given at 15–18 months of age.
    • 5th dose of DTaP or DTP at 4–6 years of age
  • Age >7 years: Primary immunization should be conducted with adult-type diphtheria and tetanus toxoids, adsorbed (Td) with 2 doses given IM at least 4 weeks apart and a booster dose 1 year later.
  • In 2005, 2 tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (TdaP) vaccines were licensed for use in adolescents 11–18 years of age.
  • 1 booster dose of TdaP should be given to all adolescents at the 11–12 year-old visit, provided they have completed the childhood series. Subsequent tetanus and diphtheria (Td) boosters should be administered every 10 years.
  • TdaP should replace the 1st dose of Td in children >10 years of age who are undergoing primary immunization (see age >7 above)
  • Isolation of patients with diphtheria is required until culture from the site of infection is negative on 3 consecutive specimens.

Diphtheria - epidemiology

  • The single known reservoir for C. diphtheriae is humans; disease is acquired by contact with either a carrier or a diseased person.
  • Most cases occur during the cooler autumn and winter months in individuals <15 years who are unimmunized.
  • Recent outbreaks have occurred, most notably in the new independent states of the former Soviet Union, and supply additional evidence that disease occurs among the socioeconomically disadvantaged living in crowded conditions.

Diphtheria - incidence

Though the disease is distributed throughout the world, it is endemic primarily in developing regions of Africa, Asia, and South America. In the Western world, the incidence of diphtheria has changed dramatically in the past 50–75 years as a result of the widespread use of diphtheria toxoid after World War II. The incidence has declined steadily and is now a rare occurrence.

Diphtheria - pathophysiology

  • The initial entry site for C. diphtheriae is via airborne respiratory droplets, typically the nose or mouth but occasionally the ocular surface, genital mucous membranes, or pre-existing skin lesions.
  • Following 2–4 days of incubation at one of these sites, the bacterium elaborates toxin.
  • Locally, the toxin induces formation of a necrotic coagulation of the mucous membranes (pseudomembrane) with underlying tissue edema; respiratory compromise may ensue.
  • Elaborated exotoxin may also have profound effects on the heart, nerves, and kidneys in the form of myocarditis, demyelination, and tubular necrosis, respectively.

Diphtheria - etiology

C. diphtheriae, a Gram-positive pleomorphic bacillus

Diphtheria - DIAGNOSIS

  • Respiratory tract diphtheria:
    • Nasal diphtheria starts with mild rhinorrhea that gradually becomes serosanguineous, then mucopurulent and often malodorous; occurs most often in infants.
    • Tonsillar and pharyngeal diphtheria begin with anorexia, malaise, low-grade fever, and pharyngitis. A membrane appears within 1–2 days. Cervical lymphadenitis and edema of the cervical soft tissues may be severe. Disease course varies with extent of toxin elaboration and membrane production. Respiratory and cardiovascular collapse may occur.
    • Laryngeal diphtheria most often represents extension of a pharyngeal infection and clinically presents as typical croup. Acute airway obstruction may occur, and in severe cases, the membrane may invade the entire tracheobronchial tree.
    • Cutaneous diphtheria occurs in warmer tropical regions. It is characterized by chronic nonhealing ulcers with gray membrane and may serve as a reservoir in endemic and epidemic areas of respiratory diphtheria.
  • Other sites: Rarely vulvovaginal, conjunctival, or aural forms occur.

Diphtheria - signs & symptoms

Diphtheria - history

  • Exposure to an individual with diphtheria is not necessarily elicited because contact with an asymptomatic carrier may be the only source of infection.
  • Incubation period:
    • Incubation period is 1–6 days.
    • Respiratory diphtheria, depending on the site of infection, may begin with nasal discharge alone or with pharyngitis accompanied by mild systemic symptoms.
    • Progression of symptoms thereafter occurs as outlined above (see “Diagnosis”).
  • Previous diphtheria immunization history, diphtheria exposure

Diphtheria - physical exam

  • Classic findings:
    • Nasal discharge
    • Nasal or pharyngeal membrane
    • Heart rate out of proportion to body temperature
    • Respiratory distress
    • Stridor
    • Cough
    • Hoarseness
    • Palatal paralysis
    • Neck swelling
    • Cervical lymphadenitis
    • Attempt to remove any membrane present results in bleeding.
  • Conjunctival diphtheria: Palpebral conjunctival involvement with a red, edematous, membranous appearance
  • Aural diphtheria: Otitis externa with a purulent, malodorous discharge
  • Cutaneous diphtheria: See “Diagnosis.”

Diphtheria - tests

Diagnosis should be on clinical grounds: Delay in treatment increases morbidity and mortality.

Diphtheria - lab

  • Culture of material from the membrane or beneath the membrane: If a strain of C. diphtheriae is isolated, additional testing for presence or absence of toxin production should be done by a laboratory prepared to conduct an animal neutralization test or, alternatively, neutralization (with antitoxin) in tissue culture.
  • Examination of a methylene blue–stained lesion: Metachromatic granules may be helpful if performed by an experienced technician.
  • Fluorescent antibody testing and counterimmunoelectrophoresis: Previously performed in state laboratories; no longer widely available

Diphtheria - differencial diagnosis

  • Nasal diphtheria:
    • Common cold
    • Nasal foreign body
    • Sinusitis
    • Adenoiditis
    • Snuffles (congenital syphilis)
  • Tonsillar or pharyngeal diphtheria:
    • Streptococcal pharyngitis
    • Infectious mononucleosis
    • Primary herpetic tonsillitis
    • Thrush
    • Vincent angina
    • Posttonsillectomy faucial membranes
    • Oropharyngeal involvement caused by toxoplasmosis, cytomegalovirus, tularemia, and salmonellosis
  • Laryngeal diphtheria:
    • Croup
    • Acute epiglottitis
    • Aspirated foreign body
    • Peripharyngeal and retropharyngeal abscess
    • Laryngeal papillomas
    • Other masses

Diphtheria - TREATMENT

Diphtheria - initial stabilization

  • Diphtheria antitoxin (DAT) antiserum, produced in horses, must be administered as soon as possible. DAT is available from the CDC. (Note: For patients with known horse serum sensitivity, a test dose should be administered 1st, and if positive, the patient should be desensitized.)
  • Pharyngeal or laryngeal disease of <48 hours duration: 20,000–40,000 units IV
  • Nasopharyngeal lesions: 40,000–60,000 units IV
  • Extensive disease of ≥3 days’ duration or diffuse neck swelling: 80,000–120,000 units IV

Diphtheria - medication

Antibiotic therapy: Use in addition to, not in place of, DAT.

  • Respiratory diphtheria:
    • Penicillin G
    • Aqueous crystalline 100,000–150,000 U/kg/d in 4 divided doses for 14 days
    • Procaine 25,000–50,000 U/kg/d in 2 divided doses for 14 days or
    • Erythromycin 40–50 mg/kg (maximum 2 g/d) PO or parenterally for 14 days
  • Cutaneous diphtheria: Requires local care of the lesion with soap and water and administration of antimicrobials for 10 days

Diphtheria - FOLLOW UP

  • Mild cases: After membrane sloughs off in 7–10 days, recovery is usually uneventful.
  • More severe cases: Recovery may be slower; serious complications may occur.

Diphtheria - prognosis

  • Most strongly dependent on the immunization status of the host. Those without prior adequate immunization have significantly higher morbidity and mortality.
  • Delay in onset of treatment also increases mortality. When appropriate treatment has been administered on day 1 of illness, mortality may be as low as 1%. When treatment has been delayed until day 4, the mortality rate is ≤20-fold higher.
  • Organism virulence: Toxigenic strains are associated with more severe disease and a poorer prognosis.
  • Location of membrane: Laryngeal diphtheria has a higher mortality owing to airway obstruction.
  • A megakaryocytic thrombocytopenia and WBC count <25,000 are associated with poor outcome.

Diphtheria - complications

  • Cardiac toxicity: Myocarditis may develop secondary to elaborated toxin anytime between the 1st and 6th week of illness. Though cardiac failure may occur, most cases are transient.
  • Neurologic toxicity occurs secondary to toxin elaboration and mainly reflects bilateral motor involvement.
  • Paralysis of the soft palate is most common, but ocular paralysis, diaphragm paralysis, peripheral neuropathy of the extremities, and loss of deep tendon reflexes also occur.
  • The frequency of all complications, including those listed above, increases with increasing time between symptom onset and antitoxin administration and also with extent of membrane formation.

Diphtheria - bibliography

    American Academy of Pediatrics. Diphtheria. In: Pickering LK, Baker CJ, Long SS, McMillan JA, eds. 2006 Red Book: Report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, Ill: American Academy of Pediatrics; 2006:277–281.
  1. Bisgard KM, Hardy IR, Popovic T, et al. Respiratory diphtheria in the United States, 1980 through 1995. Am J Public Health. 1998;88:787–791.
  2. Broder KR, Cortese MM, et al. Preventing tetanus, diphtheria, and pertussis among adolescents: Use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006;55(RR-3):1–34.
  3. Enhanced surveillance of non-toxigenic Corynebacterium diphtheriae infections. Commun Dis Rep CDR Wkly. 1996;6:29–32.
  4. Feigin RD, Stechenberg BW, Strandgaard BH. Diphtheria. In: Feigin RD, Cherry JD, eds. Textbook of Pediatric Infectious Diseases. 3rd ed. Philadelphia: WB Saunders; 1992:1110–1115.
  5. Galazka A. The changing epidemiology of diphtheria in the vaccine era. J Infect Dis. 2000;181(suppl 1): 52–59.
  6. MacGregor RR. Corynebacterium diphtheriae. In: Mandell GL, Douglas RG Jr, Bennett JE, eds. Principles and Practice of Infectious Diseases. 6th ed. New York: Churchill Livingstone; 2005:2457–2464.

Diphtheria - CODES

Diphtheria - icd9

032.9 Diphtheria, unspecified

Diphtheria - FAQ

  • Q: What is the incidence of diphtheria in the US?
  • A: From 1998–2004 7 cases of respiratory diphtheria were reported in the US.
  • Q: Are there currently places in the world where diphtheria is a problem?
  • A: Yes, an epidemic began in 1990 in Russia, spread in 1991 to Ukraine, and during 1993 and 1994, spread to the remaining new independent states of the former Soviet Union. Other endemic regions include the Middle East and Asia, and some countries in Africa and Central and South America. Traveler’s to these regions should check the CDC Web site for the latest information.
  • Q: What precautions should be taken by travelers to areas of the world with diphtheria outbreaks?
  • A: The ACIP recommends that travelers to such areas be up to date with diphtheria immunization. Infants traveling to areas where diphtheria is endemic or epidemic should receive three doses of DTP or DT before travel.
>>>

Book Source Details

  • Book Title: The 5-Minute Pediatric Consult
  • Author(s): M. William Schwartz MD; et al.
  • Year of Publication: 2008
  • Copyright Details: The 5-Minute Pediatric Consult, Copyright © 2008 Lippincott Williams & Wilkins.

More About Diphtheria

More Medical Textbooks Online about Diphtheria

Review other book chapters online related to Diphtheria:

Medical Books Excerpts
  • Diphtheria
  • "Professional Guide to Diseases (Eighth Edition)" (2005)
 

Copyright notice for book excerpts: Copyright © 2008 Lippincott Williams & Wilkins. All rights reserved.




More About This Book:
Title: The 5-Minute Pediatric Consult
Authors: M. William Schwartz MD; et al.
Publisher: Lippincott Williams & Wilkins
Copyright: 2008
ISBN: 0-7817-7577-9

 » Next page: Surveys relating to Diphtheria

Rate This Website

What do you think about the features of this website? Take our user survey and have your say:

Website User Survey

Medical Tools & Articles:

Next articles:

Tools & Services:

Medical Articles:

Forums & Message Boards

 
HONcode We subscribe to the HONcode principles

By using this site you agree to our Terms of Use. Information provided on this site is for informational purposes only; it is not intended as a substitute for advice from your own medical team. The information on this site is not to be used for diagnosing or treating any health concerns you may have - please contact your physician or health care professional for all your medical needs. Please see our Terms of Use.

Home | Symptoms | Diseases | Diagnosis | Videos | Tools | Forum | About Us | Terms of Use | Privacy Policy | Site Map | Advertise